AMBITION 3NCT07931573
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in glycated haemoglobin (HbA1c) [non-inferiority]
Timeframe: From baseline (week 0) to week 60
Secondary (6)
Relative change in body weight
Change in glycated haemoglobin (HbA1c) [superiority]
Change in triglycerides
Change in systolic blood pressure
Change in non-high density lipoprotein (non-HDL) cholesterol
Show 1 moreShow less
Change in high-sensitivity C-reactive protein (hsCRP)
Arms and interventions
ZenagamtideExperimental
Participants will receive zenagamtide subcutaneously once weekly
SemaglutideActive comparator
Participants will receive semaglutide subcutaneously once weekly
PlaceboPlacebo comparator
Participants will receive placebo matched to semaglutide or zenagamtide subcutaneously once weekly
Drugs: Zenagamtide, Semaglutide, Placebo
Sites
230 sites in 22 countries
United States 55, Germany 13, Portugal 13, Spain 12, Greece 11, United Kingdom 11, Bulgaria 9, Israel 9, Italy 9, Saudi Arabia 9, Australia 8, Czechia 8, Hungary 8, Poland 8, Romania 8, Argentina 7, Canada 7, Croatia 7, Brazil 6, Slovakia 6, Denmark 5, Puerto Rico 1